Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights

Summary

Spherix Global Insights survey reveals nephrologists identify limited treatment options as the primary challenge in Alport Syndrome management, with Filspari and Vanrafia emerging as the most desired pipeline therapies to improve renal outcomes.